Post-COVID Pulmonary Fibrosis / Sequelae

Post-COVID Pulmonary Fibrosis / Sequelae is indexed under Long COVID & Post-Infectious Syndromes, Post-COVID Organ-Specific. Also known as PASC pulmonary.

US prevalence

~2-6% of hospitalized COVID patients develop persistent fibrotic changes Source: ATS; Lancet Resp Med 2022. This figure comes from a professional society, registry, or study rather than a federal source. Label: REPORTED.

ICD-10-CM codes

U09.9, J84.10

Typical onset

Primarily post-severe COVID; ICU survivors

Course

managed

Body systems

pulmonary

Sex differences

Male predominance for severe COVID

Racial and ethnic differences

Follows COVID severity disparities

What this page does not establish

These figures describe populations, not individuals, and none of them is a diagnosis or a treatment recommendation. Prevalence estimates are approximate and reflect published ranges. Disparity figures are reported patterns, not causes.

Taxonomy last reviewed 2026-05-19. Each figure on the interactive page carries its own source and retrieval date, which can be later than this review.

Browse all indexed conditions · Source registry · Methodology · Known limitations